0

532041

HINDBIO

img img img img
No Data Available

HINDUSTAN BIO SCIENCES LTD. Share Price Update

As of the latest trading session, HINDUSTAN BIO SCIENCES LTD. is trading at ₹9, down by ₹-0.09 or -0.99% from its previous close. The stock has moved between ₹8.66 and ₹9.15 today. Over the past year, the stock has delivered a return of 20.87%. In the last month, it has returned 12.49%.

Investment Returns

Over 1 Month 12.49% Over 3 Months 6.44% Over 6 Months 30.41% Over 1 Year 20.87%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

HINDUSTAN BIO SCIENCES LTD. fundamentals


  • Market cap (Cr) [-]
  • P/E Ratio (TTM) [-]
  • Beta [-]
  • Book Value / share [-]
  • Return on equity [-]%
  • EPS (TTM) [-]
  • Dividend yield [-]%
  • Net profit/quarter (Cr) [-]
info icon alternate text
  • Market cap (Cr) 9.40
  • P/E Ratio (TTM) 64.93
  • Beta 0.27
  • Book Value / share 0.83
  • Return on equity 4.88%
  • EPS (TTM) 0.14
  • Dividend yield [-]%
  • Net profit/quarter (Cr) 0.08
info icon alternate text

HINDUSTAN BIO SCIENCES LTD. Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars DEC 2025 (Values in Cr)
Revenue 0.38
Operating Expense 0.32
Net Profit 0.08
Net Profit Margin (%) 21.05
Earnings Per Share (EPS) 0.08
EBITDA 0.09
Effective Tax Rate (%) 0.00
Particulars SEP 2025 (Values in Cr)
Revenue 0.00
Operating Expense 0.07
Net Profit -0.06
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) -0.06
EBITDA -0.06
Effective Tax Rate (%) 0.00
Particulars JUN 2025 (Values in Cr)
Revenue 0.32
Operating Expense 0.32
Net Profit 0.01
Net Profit Margin (%) 3.12
Earnings Per Share (EPS) 0.01
EBITDA 0.01
Effective Tax Rate (%) 0.00
Particulars MAR 2025 (Values in Cr)
Revenue 0.38
Operating Expense 0.28
Net Profit 0.11
Net Profit Margin (%) 28.94
Earnings Per Share (EPS) 0.11
EBITDA 0.11
Effective Tax Rate (%) 0.00
Particulars DEC 2024 (Values in Cr)
Revenue 0.00
Operating Expense 0.04
Net Profit -0.04
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) -0.04
EBITDA -0.04
Effective Tax Rate (%) 0.00
Particulars MAR 2025 (Values in Cr)
Revenue 0.81
Operating Expense 0.71
Net Profit 0.10
Net Profit Margin (%) 12.34
Earnings Per Share (EPS) 0.10
EBITDA 0.10
Effective Tax Rate (%) 0.00
Particulars MAR 2024 (Values in Cr)
Revenue 1.03
Operating Expense 1.00
Net Profit 0.06
Net Profit Margin (%) 5.82
Earnings Per Share (EPS) 0.06
EBITDA 0.06
Effective Tax Rate (%) 0.00
Particulars MAR 2023 (Values in Cr)
Revenue 0.92
Operating Expense 0.96
Net Profit -0.04
Net Profit Margin (%) -4.34
Earnings Per Share (EPS) -0.04
EBITDA -0.03
Effective Tax Rate (%) 0.00
Particulars MAR 2022 (Values in Cr)
Revenue 0.43
Operating Expense 0.95
Net Profit -0.52
Net Profit Margin (%) -120.93
Earnings Per Share (EPS) -0.50
EBITDA -0.50
Effective Tax Rate (%) 0.00
Particulars MAR 2021 (Values in Cr)
Revenue 1.03
Operating Expense 1.99
Net Profit -0.94
Net Profit Margin (%) -91.26
Earnings Per Share (EPS) -0.92
EBITDA -0.94
Effective Tax Rate (%) 2.08
Particulars MAR 2025 (Values in Cr)
Book Value / Share 0.88
ROE % 4.88
ROCE % 2.18
Total Debt to Total Equity 2.98
EBITDA Margin 12.35
Particulars MAR 2024 (Values in Cr)
Book Value / Share 0.78
ROE % 4.29
ROCE % 1.53
Total Debt to Total Equity 3.24
EBITDA Margin 5.71
Particulars MAR 2023 (Values in Cr)
Book Value / Share 3.64
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 3.01
EBITDA Margin -3.26
Particulars MAR 2022 (Values in Cr)
Book Value / Share 0.77
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 1.93
EBITDA Margin -118.60
Particulars MAR 2021 (Values in Cr)
Book Value / Share 1.27
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 1.26
EBITDA Margin -91.26
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 0.01
Total Assets 3.42
Total Liabilities 3.42
Total Equity 0.90
Share Outstanding 1
Price to Book Ratio 7.93
Return on Assets (%) 2.94
Return on Capital (%) 2.95
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 0.03
Total Assets 3.37
Total Liabilities 3.37
Total Equity 0.80
Share Outstanding 1
Price to Book Ratio 9.29
Return on Assets (%) 1.70
Return on Capital (%) 1.71
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.00
Total Assets 3.28
Total Liabilities 3.28
Total Equity 0.74
Share Outstanding 0
Price to Book Ratio 1.46
Return on Assets (%) -1.23
Return on Capital (%) -1.26
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.00
Total Assets 2.97
Total Liabilities 2.97
Total Equity 0.78
Share Outstanding 1
Price to Book Ratio 5.48
Return on Assets (%) -17.39
Return on Capital (%) -17.52
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 0.01
Total Assets 3.48
Total Liabilities 3.48
Total Equity 1.30
Share Outstanding 1
Price to Book Ratio 2.36
Return on Assets (%) -26.95
Return on Capital (%) -29.71
Particulars MAR 2025 (Values in Cr)
Net Income 0.09
Cash from Operations 0.02
Cash from Investing 0.00
Cash from Financing -0.05
Net change in Cash -0.02
Free Cash Flow 0.02
Particulars MAR 2024 (Values in Cr)
Net Income 0.05
Cash from Operations -1.40
Cash from Investing 0.00
Cash from Financing 1.43
Net change in Cash 0.02
Free Cash Flow -1.40
Particulars MAR 2023 (Values in Cr)
Net Income -0.03
Cash from Operations -0.04
Cash from Investing 0.00
Cash from Financing 0.05
Net change in Cash 0.00
Free Cash Flow -0.04
Particulars MAR 2022 (Values in Cr)
Net Income -0.51
Cash from Operations -0.34
Cash from Investing 0.00
Cash from Financing 0.33
Net change in Cash 0.00
Free Cash Flow -0.33
Particulars MAR 2021 (Values in Cr)
Net Income -0.95
Cash from Operations 0.73
Cash from Investing 0.00
Cash from Financing -0.93
Net change in Cash -0.17
Free Cash Flow 0.73
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 31.79 13.76 1.65 243.62 23.12 40.44
BLISS GVS PHARMA LTD 271.90 25.99 2.54 2876.40 105.05 280.20
CIPLA LTD 1362.85 23.15 3.34 110088.66 1165.55 1672.20
FERMENTA BIOTECH LIMITED 300.95 10.01 2.26 885.73 252.15 399.00
GLAXOSMITHKLINE PHARMACEUTICAL 2478.95 41.75 24.59 41994.91 2218.00 3515.95
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 31.79 30.57 4.43 243.62 23.12 40.44
AMRUTAJAN HEALTH LTD 558.60 27.93 4.72 1614.95 490.00 789.95
ASTRAZENECA PHARMA INDIA LTD. 8535.30 102.58 26.70 21338.25 7630.00 10653.05
BLISS GVS PHARMA LTD 271.90 37.04 2.60 2876.40 105.05 280.20

HINDUSTAN BIO SCIENCES LTD. shareholding pattern

Holding
87.8%
12.19%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

HINDUSTAN BIO SCIENCES LTD. Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
9.15 0.66 redarrow
red-green-graph indicator
1 Bearish
15 Bullish
  • 5 Days 9.00
  • 26 Days 8.80
  • 10 Days 9.00
  • 50 Days 8.40
  • 12 Days 9.00
  • 100 Days 8.00
  • 20 Days 8.90
  • 200 Days 7.90
8.82 PIVOT
First Support 8.53 First Resistance 9.39 Second Support 7.96 Second Resistance 9.68 Third Support 7.67 Third Resistance 10.25
RSI 55.28 ADX 73.05 MACD 0.21 Williams % R -50.00 Commodity Channel Index (CCI) -93.34
Date 2026-05-07 Week 11384.00 Same Day 15253.00 Month 10887.00
1 Year 0.27 3 Year 0.18
Over 1 Month
12.49% down
Over 1 Year
20.87% down
Over 3 Months
6.44% down
Over 3 Years
2.78% down
Over 6 Months
30.41% down
Over 5 Years
12.92% down

HINDUSTAN BIO SCIENCES LTD. Corporate Actions

Top Gainers

Top Losers

HINDUSTAN BIO SCIENCES LTD. Share Price

Hindustan Bio Science Limited was initially incorporated as Garuda Cements Limited in December 1991. Earlier, it was engaged in cement manufacturing and due to sluggish in the industry, the Company diversified its business into Bio Technology & Pharmaceuticals activities in 2000-01 and the name was changed from Garuda Cements Limited to Hindustan Bio-Sciences Limited. In 2002, it diversified into software field and subsequently changed its name to Hindustan Bio Sciences Limited on August 8, 2002.

The Company engaged in the manufacturing and sale of pharmaceutical products is an integrated firm with diversified businesses in pharmaceutical and biotechnology industries. The Company initially commenced operations in 1992 by sourcing bulk drugs (APIs) and drug intermediates for the Industry with a wellspring of global suppliers and associates. It acquired the shares of Venkar Chemicals Ltd in 2004 and upon the acquisition, it became Wholly owned subsidiary of the Company with effect from 19.08.2004.

During 2006-07, Company got approval from Drugs Controller General of India (DCGI) and started marketing the nephrology product 'Recombinant Human Erythropoietin' with the brand name 'EPOVIN' from June, 2007.

The Company operate its manufacturing plants for dry and liquid injectables, liquid/dry syrups, Eye/Ear/Nasal drops, pre-filled syringes and non sterile/sterile ointments, tablets and capsules approved by several regulatory authorities and is trusted by healthcare professionals and patients across the globe. Presently, it is now manufacturing and marketing finished dosage forms of pharmaceutical products.

Parent organization Indian Private
NSE symbol [-]
Founded 1991
stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of [-]?

Answer Field

[-] share price is for NSE ₹ [-] & for BSE ₹ [-] as on May 08 2026 12:14 PM.

What is the Market Cap of [-] Share?

Answer Field

The market cap of [-] for NSE ₹ [-] & for BSE ₹ [-] as on May 08 2026 12:14 PM.

What is the 52 Week High and Low of [-]?

Answer Field

The 52 Week High and Low of [-] for NSE is ₹ [-] and ₹ [-] and for BSE is ₹ [-] and ₹ [-].

What is 1 year return for [-]?

Answer Field

The 1 year returns on the stock has been [-]%.

What is the P/E Ratio of [-] Share?

Answer Field

As on May 08 2026 12:14 PM the price-to-earnings (PE) ratio for [-] share is 64.93.

What is the PB ratio of [-] Share?

Answer Field

As on May 08 2026 12:14 PM, the price-to-book (PB) ratio for [-] share is 0.83.

How to Buy [-] Share on Bajaj Broking App?

Answer Field

To buy [-] shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “[-]”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|